SCHEMBL770485

SCHEMBL770485

CC1CCN(C(=O)C(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.38
HPGD P15428 7/20 0.38
ALDH1A1 P00352 6/20 0.38
TP53 P04637 1/20 0.38
NPC1 O15118 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
RAB9A P51151 1/20 0.36
LIPE Q05469 1/20 0.36
GAA P10253 1/20 0.35
KMT2A Q03164 3/20 0.35
GRM5 P41594 1/20 0.35
POLB P06746 1/20 0.35
CYP1A2 P05177 1/20 0.35
MAPT P10636 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772492 0.91 L3MBTL3 (0.33) HPGDALDH1A1TP53NPC1SMN1; SMN2
SCHEMBL770905 0.88 ALDH1A1 (0.36) HPGDALDH1A1GAAKMT2ALMNA
SCHEMBL769878 0.88 KMT2A (0.36) HPGDALDH1A1SMN1; SMN2CA12CA1
SCHEMBL771570 0.87 L3MBTL3 (0.37) HPGDALDH1A1SMN1; SMN2KMT2APOLB
SCHEMBL771057 0.87 RECQL (0.42) HPGDALDH1A1NPC1SMN1; SMN2CA12
SCHEMBL770413 0.85 RBP4 (0.38) HPGDALDH1A1TP53NPC1SMN1; SMN2
SCHEMBL770939 0.85 NPC1 (0.49) HPGDALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL770075 0.85 ALDH1A1 (0.42) HPGDALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL771478 0.84 ALDH1A1 (0.38) HPGDALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL769997 0.83 NPC1 (0.54) HPGDALDH1A1NPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ACHE 656/4885HPGD 50/4885ALDH1A1 144/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 ACHE 677/4885HPGD 50/4885ALDH1A1 142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.